164 related articles for article (PubMed ID: 10569202)
21. Molecular cloning and characterization of MHC class I- and II-restricted tumor antigens recognized by T cells.
Wang RF
Curr Protoc Immunol; 2009 Feb; Chapter 20():20.10.1-20.10.29. PubMed ID: 19235768
[TBL] [Abstract][Full Text] [Related]
22. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
23. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
24. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
25. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
26. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
[TBL] [Abstract][Full Text] [Related]
27. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
28. T cells work together to fight cancer.
Cerundolo V
Curr Biol; 1999 Sep; 9(18):R695-7. PubMed ID: 10508600
[TBL] [Abstract][Full Text] [Related]
29. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
30. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Nishimura MI; Avichezer D; Custer MC; Lee CS; Chen C; Parkhurst MR; Diamond RA; Robbins PF; Schwartzentruber DJ; Rosenberg SA
Cancer Res; 1999 Dec; 59(24):6230-8. PubMed ID: 10626817
[TBL] [Abstract][Full Text] [Related]
31. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
Dhiman G; Lohia N; Jain S; Baranwal M
Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
[TBL] [Abstract][Full Text] [Related]
32. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
SenGupta D; Norris PJ; Suscovich TJ; Hassan-Zahraee M; Moffett HF; Trocha A; Draenert R; Goulder PJ; Binder RJ; Levey DL; Walker BD; Srivastava PK; Brander C
J Immunol; 2004 Aug; 173(3):1987-93. PubMed ID: 15265933
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
[TBL] [Abstract][Full Text] [Related]
34. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
35. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
36. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
[TBL] [Abstract][Full Text] [Related]
37. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines.
Accolla RS; Tosi G
J Transl Med; 2012 Jul; 10():154. PubMed ID: 22849661
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.
Grohmann U; Fioretti MC; Bianchi R; Belladonna ML; Ayroldi E; Surace D; Silla S; Puccetti P
Crit Rev Immunol; 1998; 18(1-2):87-98. PubMed ID: 9419451
[TBL] [Abstract][Full Text] [Related]
39. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.
Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CG; Steinitz M; Fagerberg J; Mellstedt H
Clin Cancer Res; 2004 Aug; 10(16):5391-402. PubMed ID: 15328177
[TBL] [Abstract][Full Text] [Related]
40. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Topalian SL
Curr Opin Immunol; 1994 Oct; 6(5):741-5. PubMed ID: 7826529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
